Azitra, Inc. Announces Reverse Stock SplitPRNewsWire · Oct 16, 2026
Azitra, Inc. Advances ATR-04 Phase 1/2 Clinical Trial to Cohort 2 Following Safety Review Committee ClearancePRNewsWire · Oct 1, 2026
Azitra, Inc. (NYSEAMERICAN:AZTR) Sees Significant Drop in Short InterestDefense World · Sep 29, 2026
Azitra, Inc. to Present at the H.C. Wainwright 28th Annual Global Investment ConferencePRNewsWire · Sep 8, 2026
Azitra, Inc. Regains Compliance with NYSE American Continued Listing StandardsPRNewsWire · Aug 21, 2026
Azitra, Inc. Announces Q2 2026 Results and Provides Business UpdatesPRNewsWire · Aug 12, 2026Azitra, Inc. is a pre-clinical biopharmaceutical company focused on developing precise treatments for various dermatological conditions. They innovate by utilizing engineered proteins and live biotherapeutic products to address skin diseases. The company's pipeline features several key therapeutic candidates: ATR-12: A genetically modified strain of S. epidermidis intended to treat Netherton syndrome, a specific skin disorder.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 12, 2026 | -$0.12 | -$0.17 | Miss |
| May 12, 2026 | -$0.01 | -$0.25 | Miss |
| Mar 2, 2026 | -$0.37 | -$1.15 | Miss |
| Nov 12, 2025 | -$0.79 | -$0.67 | Beat |
| Aug 11, 2025 | -$1.40 | -$1.20 | Beat |
| May 13, 2025 | – | -$1.53 |